Downloads: 95

Files in This Item:
File Description SizeFormat 
cam4.974.pdf196.02 kBAdobe PDFView/Open
Title: High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation
Authors: Sakamoto, Soichiro
Kawabata, Hiroshi
Kanda, Junya  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-6704-3633 (unconfirmed)
Uchiyama, Tatsuki
Mizumoto, Chisaki
Kitano, Toshiyuki
Kondo, Tadakazu  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-8959-6271 (unconfirmed)
Hishizawa, Masakatsu
Tomosugi, Naohisa
Takaori-Kondo, Akifumi
Author's alias: 川端, 浩
Keywords: Allogeneic hematopoietic stem cell transplantation
engraftment
hepcidin
iron
Issue Date: Jan-2017
Publisher: Wiley-Blackwell
Journal title: Cancer Medicine
Volume: 6
Issue: 1
Start page: 120
End page: 128
Abstract: Iron overload is considered a risk factor for mortality in patients with hematopoietic malignancies. Hepcidin is a key regulator of systemic iron balance. We previously reported dynamic changes of serum hepcidin-25 levels in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this study, we retrospectively analyzed the association of pretransplant hepcidin-25 levels with overall survival (OS), engraftment, and other clinical outcomes of allo-HSCT in patients with hematologic malignancies. A total of 166 patients were divided into two groups depending on their pretransplant serum hepcidin-25 levels; their median age was 49.5 years, and the median follow-up time was 46.8 months. At 3 years, the patients in the high-hepcidin group had a significantly lower OS than those in the low-hepcidin group (49.2 vs. 69.0%, respectively; P = 0.006). Multivariate analysis revealed that pretransplant serum hepcidin-25 level, sex, and disease status were independently associated with OS. The incidence of platelet engraftment was significantly lower in the high-hepcidin group than in the low-hepcidin group, whereas no significant differences were observed in neutrophil and reticulocyte engraftments between these groups. Hence, pretransplant serum hepcidin levels can be a marker for predicting delayed platelet recovery after allo-HSC
Rights: © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
URI: http://hdl.handle.net/2433/218756
DOI(Published Version): 10.1002/cam4.974
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.